DOCSLIB.ORG

Short Contact Dithranol for Psoriasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Short Contact Dithranol for Psoriasis Page 1 of 2 Short Contact Dithranol for Psoriasis A course of dithranol ointment or cream often works well to clear plaque psoriasis. One drawback is that it can irritate skin and stain clothing. These effects can be minimised if dithranol is used for a short period each day and the strength is gradually increased to the strongest tolerated. Follow the instructions carefully that come with the preparation you are prescribed for the best chance of success and minimal problems. What is psoriasis? Psoriasis is a common skin condition which commonly develops as patches ('plaques') of red, scaly skin. Treatment aims to clear the rash as much as possible. However, as psoriasis tends to 'come and go', you may need courses of treatment 'on and off' throughout your life. There are various treatments. There is no 'best buy' that suits everybody. The treatment advised by your doctor may depend on the severity, location and type of psoriasis. Also, one treatment may work well in one person, but not in another. This leaflet is just about dithranol for the treatment of psoriasis. There are separate leaflets on psoriasis in general, and on the other common topical treatments for psoriasis - vitamin D analogues, coal tar, steroid creams and tazarotene. What is dithranol and short contact dithranol treatment? Dithranol is a drug that has been used in the treatment of psoriasis for over 50 years. There are various ointments and creams that contain different strengths of dithranol. Dithranol is usually a safe treatment and will clear psoriatic plaques in many people with psoriasis. As a rule, dithranol is only used to treat the classical plaques (larger patches) of psoriasis. It is not usually suitable for widespread small patches of psoriasis that some people develop. Also, it should not be used in the skin creases or flexures (front of elbows, behind knees, armpits, groins, etc) or on the face unless supervised by a specialist. This is because of the risk of irritating the skin in the skin creases and irritating the eyes with dithranol. Dithranol can irritate if it comes into contact with normal skin around treated patches of psoriasis. It can also stain clothing and fabrics that come into contact with it. These problems can be minimised if dithranol is used for a short period every day ('short contact') and the strength is gradually increased so that the skin becomes used to the treatment. How to use dithranol for short contact treatment Follow the instructions given by your doctor carefully, and on the packet of the preparation that you are prescribed. Also, persevere with the treatment as success often takes several weeks. The instructions may include the following: Wear plastic disposable gloves when applying dithranol cream or ointment. Wash hands thoroughly after applying dithranol. Apply only to the plaques of psoriasis. Avoid putting it on normal skin. For creams, apply sparingly, rub in well and wipe off any excess. For ointments, apply sparingly. Avoid getting any in or near the eyes. If eye irritation occurs wash thoroughly with water and if it persists, see your doctor. Leave the cream or ointment on for as long as directed by your doctor. For short contact treatment, this may be anything from 5-60 minutes. Then wash it off. When washing off, just use cool water (below 30C) without soap or detergent. Hot water or soap may cause increased staining of the skin by the dithranol. You can use hot water and soap to wash after the cream or ointment has been rinsed off. Page 2 of 2 A common treatment plan is to start with a low strength preparation of dithranol. If there is no irritation then apply daily as directed (often for about 30 minutes each day) for a few days. The strength is then increased to a stronger preparation which is continued for a further few days before moving on to a higher strength, etc. The aim is to gradually build up the strength (the % concentration) to the strongest preparation you can tolerate. If irritation or burning occurs, stop using dithranol and apply a moisturiser until the skin has settled. Then start again at a lower strength. Some people are more sensitive to the irritating and burning effects than others. So, different people end up using different strengths. Carry on with the treatment until the treated skin feels flat and smooth like the nearby normal skin. Any staining of the skin will clear, usually in about two weeks. If you have problems with skin irritation, or if there is no improvement after three weeks at the highest strength you can tolerate, then see your doctor for advice. Dithranol can stain Dithranol stains normal skin a brownish colour. This is temporary and will gradually fade. It may also stain clothes, sheets, furnishings, etc, if they come into contact with dithranol. This staining can be permanent. So, when using dithranol, wear old clothes that you don't mind if they become stained. Baths may also be stained. If possible, have a shower rather than a bath after using dithranol treatment. If you have a bath, clean it immediately with detergent. A little vinegar added to rinse water helps to reduce staining. If staining of the skin occurs in the centre of the plaques of psoriasis, this means the psoriasis is starting to clear. How safe is dithranol? Although during treatment dithranol may irritate or slightly burn normal skin, and may stain skin or clothes, it is generally a safe treatment. It has been used for many years and, if used properly, is not known to cause any long term side-effects or problems. Further sources of information Psoriasis Association Dick Coles House, 2 Queensbridge, Bedford Road, Northampton NN4 7BF Tel (helpline): 0845 6 760 076 Web: www.psoriasis-association.org.uk References Psoriasis - General Management, British Association of Dermatologists (2008) Lui H; Psoriasis, Plaque. eMedicine, February 2007. British National Formulary Comprehensive patient resources are available at www.patient.co.uk Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions. © EMIS 2009 Reviewed: 5 Feb 2008 DocID: 4234 Version: 39.
Load more

Recommended publications
  • A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: the Effect on Keratinocyte Subpopulations
    Acta Derm Venereol 2004; 84: 195–200 INVESTIGATIVE REPORT A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF Department of Dermatology, University Medical Centre Nijmegen, The Netherlands Vitamin D3 analogues are a first-line treatment of Calcipotriol (Daivonex1,50mg/g ointment, Leo chronic plaque psoriasis, but so far, comparative clinical Pharmaceutical Products, Denmark) has been investi- studies on calcipotriol and calcitriol ointment are sparse, gated intensively during the last decade, and has proven and in particular no comparative studies are available on to be a valuable tool in the management of chronic cell biological effects of these compounds in vivo. Using plaque psoriasis. A review by Ashcroft et al. (1), based on flow cytometric assessment, we investigated whether these a large number of randomized controlled trials, showed compounds had different effects on the composition and that calcipotriol was at least as effective as potent DNA synthesis of epidermal cell populations responsible topical corticosteroids, 1a,-25-dihydroxycholecalciferol for the psoriatic phenotype. For 8 weeks, 20 patients with (calcitriol), short-contact dithranol, tacalcitol and coal psoriasis vulgaris were treated twice daily with calcipo- tar. Recently, Scott et al. (2) presented an overview of triol and calcitriol ointment in a left/right comparative studies on the use of calcipotriol ointment in the study. Before and after treatment, clinical assessment of management of psoriasis. They reconfirmed the super- target lesions was performed, together with flow cyto- ior efficacy of a twice-daily calcipotriol ointment metric analysis of epidermal subpopulations with respect regimen to the treatments as mentioned above, and to keratin (K) 10, K6, vimentin and DNA distribution.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies
    Reviews 1447 Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies Authors Anna Herman1, Andrzej P. Herman 2 Affiliations 1 Faculty of Cosmetology, The Academy of Cosmetics and Health Care, Warsaw, Poland 2 Laboratory of Molecular Biology, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Jabłonna, Poland Key words Abstract several electronic databases and literature refer- l" Psoriasis ! ences were used to summarize the current l" herbal products Psoriasis is a chronic inflammatory skin disease knowledge acquired on the basis of animal stud- l" keratinocyte hyper- characterized histologically by hyperproliferation ies and clinical trials regarding herbal products proliferation and aberrant differentiation of epidermal kerati- used to treat psoriasis topically. This review dis- l" inflammatory reaction l" skin barrier nocytes. A wide range of conventional medical cusses the mechanisms of herbal products activ- l" herbal drug delivery systems therapies to treat psoriasis is established, from ities through (1) inhibition of the keratinocyte hy- topical therapies and systemic medications perproliferation and inducing apoptosis, (2) inhi- through to phototherapy or combinations of bition of immune-inflammatory reaction, (3) those. However, most of these therapies have a suppression of phosphorylase kinase (PhK) activ- limited efficacy and may cause a number of side ity, and (4) inhibition of the hedgehog (Hh) sig- effects, including cutaneous atrophy, organ toxic- naling pathway. Moreover, the penetration of ity, carcinogenicity, and broadband immunosup- herbal products through the psoriatic skin barrier, pression, which are restricting their long-term novel herbal drug delivery systems in psoriasis use. Therefore, it would be desirable to use herbal treatment, and possible adverse effects of herbal products as an alternative treatment for psoriasis therapy are discussed.
    [Show full text]
  • CMP 2 Psoriasis with Acitretin/Methotrexate
    1CMP Psoriasis with Acitretin Name of Patient: Patient medication sensitivities/allergies: Patient identification e.g. ID number, date of birth: Current medication: Medical history: Independent Prescriber(s): Supplementary prescriber(s): Dr Sam Gibbs Jill Peters Dermatology Nurse Practitioner Contact details: 01473 704042 Contact details: 01473 704386 or 0787056578 [email protected] [email protected] Condition(s) to be treated: Aim of treatment: Psoriasis – scalp, flexural, guttate, small and large To achieve temporary clearance of the psoriasis or a maintainable plaque and palmer planter psoriasis level of clearance for the patient Medicines that my be prescribed by SP: Preparation Indication Dose schedule Specific indications for referral (All listed preparation may be back to the IP used as sole or conjunct therapy) Mild to potent topical Guttate or small plaque, As detailed in BNF Acute exacerbation or Failure to steroids palmo plantar psoriasis. Finger tip units respond to treatment Cautious use on face and flexural areas (moderate) Facial, scalp or flexural, palmo plantar psoriasis Coal Tar preparations Guttate or small plaque including scalp Dithranol preparations Moderate to large plaque As detailed in BNF as short stable psoriasis contact therapy Salicylic acid 2-10% in WSP Hyperkeratotic psoriasis on scalp or palmo plantar Vitamin D analogue Second line therapy to Use for 4 weeks and then change combined with potent topical moderate/large plaque to Vitamin D alone steroid psoriasis if unresponsive
    [Show full text]
  • H.9 Dithranol, Coal Tar and Vitamin D Analogues Combined with UVB
    Psoriasis Evidence Tables – Clinical Studies H.9 Dithranol, coal tar and vitamin D analogues combined with UVB H.9.1 Calcipotriol + NB-UVB versus Calcipotriol Reference Study type Number of Patient characteristics Interventio Compariso Length Outcome Source patients n n of measures follow- of up fundin g Not A.V. Roussaki- RCT Total N = 45 Inclusion criteria: Group A Group C 3 1º stated Schulze, C. month Outcome: Kouskoukis, E. Single centre, Patients with plaque psoriasis s Klimi, E. PASI Greece Pts randomised N=15 N=15 reduction Zafirou, A. to three Galanous, E. groups: A, B Exclusion criteria: Rallis. &C. Group B Calcipotriol Randomised: Pregnant women, history of skin Calcipotriol Calcipotriol PASI 50 not relevant cancer ointment ointment monotherapy Method not (UVA+calcipotri versus (Dovonex; (Dovonex stated ol) 50 µg/g, 50 µg/g, calcipotriol Other plus UVA1 Baseline characteristics of b.d.) b.d.) + NB- UVB* outcomes versus randomised patients: : calcipotriol Allocation (twice plus narrow- concealment: weekly) Clear band UVB in Calcipotriol Calcipotriol + Not mentioned the treatment NB-UVB of psoriasis. NB-UVB Non- Drugs Exptl. M/F 12/3 12/3 starting Blinding: responder Psoriasis Evidence Tables – Clinical Studies Cl in. Res , dose 80% 31(5/6):169- Not mentioned Age 44.93±6.48 49.53±22.01 MED and 174.2005 inc. by 20% Skin type 0/11/3/1 2/5/6/2 I/II/III/IV every 3 REFID: Washout sessions ROUSSAKISCH period: ULZE2005 90 days if using systemic *Cosmetico therapy, 30 days , 10 lamps if using topicals Helarium B1, 100 W each.
    [Show full text]
  • Daivonex, Topical Ointment
    NEW ZEALAND DATA SHEET 1 DAIVONEX® 50 microgram/gram topical ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Daivonex® ointment contains calcipotriol 50 microgram per gram Daivonex® ointment contains the anhydrous form of calcipotriol. For full list of excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Daivonex® is a topical ointment. It is a smooth, white preservative free ointment base. 4 CLINICAL PARTICULARS 4.1 Indications Daivonex® ointment is indicated for the topical treatment of psoriasis vulgaris, including plaque psoriasis in adults and children (see section 4.4 Special warnings and precautions for use - paediatric population). In adult patients, Daivonex® ointment may also be used in combination with systemic acitretin or cyclosporin. 4.2 Dosage and method of administration Adults Daivonex® ointment therapy: Daivonex® ointment should be applied topically to the affected area once or twice daily (i.e. in the morning and/or in the evening). Initially, twice daily application of the ointment is usually preferred. Application may then be reduced to once daily, provided individual clinical response is satisfactory. After satisfactory improvement has occurred, treatment should be discontinued. If recurrence develops after reduction in frequency of application or after discontinuation, the treatment may be reinstituted at the initial dosage. Experience is lacking in the use of calcipotriol for periods longer than 1 year. The maximum recommended weekly dose of Daivonex® ointment is 100 g/week. When using a combination of ointment and cream the total maximum dose should not exceed 100 g per week. eDoc-000783454 - Version 1. 0 It should be noted that there are no long-term clinical studies assessing the safety of using Daivonex® ointment during exposure to sunlight.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Calcipotriol/Betamethasone Dipropionate: Daivobet®/Dovobet®
    DRUG PROFILE Calcipotriol/betamethasone dipropionate: Daivobet®/Dovobet® Lyn C Guenther Psoriasis is a common skin condition that causes significant morbidity. Treatments can be 835 Richmond St., complex and time consuming. Calcipotriol plus betamethasone dipropionate ointment London, Ontario, (Daivobet® or Dovobet®) is a stable, convenient, once-daily topical treatment for psoriasis. N6A 3H7, Canada Tel.: +1 519 435 1738 Compared with its individual ingredients or tacalcitol, it has a faster speed of onset and Fax: +1 519 435 1740 greater efficacy. Consistent Psoriasis Area Severity Index reductions of approximately 40% [email protected] after 1 week and 70% after 4 weeks were seen in multicenter studies involving more than 6000 patients. After 4 weeks of once-daily therapy, approximately 50% of patients are clear or almost clear. This product is associated with a similar safety profile to betamethasone dipropionate ointment, 50% fewer cutaneous adverse events than calcipotriol ointment and 75% fewer than tacalcitol ointment. Psoriasis affects 0.3 to 2.6% of the population and receptor, acts as a heterodimer with the retinoid X has a significant impact on the patient’s quality of receptor (RXR) [9]. Keratinocytes and lympho- life [1–4]. A 1998 US survey of 17,488 National cytes have vitamin D receptors. In psoriasis, Psoriasis Foundation patient members showed that vitamin D analogues normalize differentiation psoriasis had a significant impact on psychosocial and proliferation, induce apoptosis in inflamma- activities (e.g., interacting in the workplace and tory cells, induce a T-helper (Th)1 to 2 switch with family/spouse, making and keeping friends, and are antiangiogenic [10–12].
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Analytical Methods for the Determination of Anti-Psoriatic Drugs - a Review
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 4 Issue 2 February 2020 Review Article Analytical Methods for the Determination of Anti-Psoriatic Drugs - A Review Sistla Mounica Pratyusha* and Choppala Asha Deepti Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute Received: January 20, 2020 of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, Published: January 31, 2020 India © All rights are reserved by Sistla Mounica *Corresponding Author: Sistla Mounica Pratyusha, Department of Pharma- Pratyusha and Choppala Asha Deepti. ceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, India. DOI: 10.31080/ASPS.2020.04.0490 Abstract Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. Typical psoriatic scales are in thick, red patches. Sometimes, these patches will crack and bleed. Psoriasis is the result of a sped-up skin production process. Some of the drugs used in the treatment of psoriasis are Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calcipotriol, Anthralin etc. A brief review of the analytical methods developed for the determination of drugs used for the treatment of Psoriasis was discussed in the present study. Keywords: Acitretin; Etretinate; Bergapten Introduction Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells. This build-up of cells causes scaling on the skin’s surface. Typically, skin cells grow deep in the skin and slowly rise to the surface. The typical life cycle of a skin cell is one month. Some of the drugs used in the treatment of psoriasis: Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calci- potriol, Anthralin and the chemical structures of these drugs were - termination of these drugs were summarized in table 1.
    [Show full text]
  • H.6 Topical Therapies for Chronic Plaque Psoriasis – Trunk and Limbs
    Psoriasis Evidence Tables – Clinical Studies H.6 Topical therapies for chronic plaque psoriasis – trunk and limbs H.6.1 VITAMIN D OR VITAMIN D ANALOGUE VS POTENT CORTICOSTEROID Reference Study type Number Patient characteristics Intervention Compariso Length of Outcome Source of n follow-up measures patients of funding J. M. Galder Camarasa, J. Multicentre (20 N=258 INCLUSION CRITERIA N=128 N=130 Treatment Primary ma P. Ortonne, centres in Europe) duration : outcome : Laborat Adults, moderate to severe Calcitriol 3 0.05% 6 weeks and L. chronic plaque psoriasis (≥ 2 on µg/g betametha IAGI (6-pt: ories Dubertret. Drop-outs (or until global severity score) sone complete worse to Calcitriol DESIGN (don’t dipropiona cleared) shows complete EXCLUSION CRITERIA clearance) Between patient Formulation : te greater the persistence study): Systemic or intralesional ointment Patient delivery therapy or PASI of Post- treatment ALLOCATION N =15 photo(chemo)therapy in Formulatio treatment previous two mths; medications n: ointment effect than Frequency follow-up : betamethas Random or conditions that might 8 wk for interfere with the assessment twice daily one Method of 6 (4.7%) those who dipropionat calcitriol of study drugs; concomitant Frequency were at Relapse randomisation: not bacterial, fungal or viral skin rate e in topical reported and 9 least psoriasis (6.9%) conditions; clinically relevant Who twice daily considerab abnormalities in laboratory therapy. Concealment: betameth administered le J.Dermatol. unclear asone parameters (calcium not
    [Show full text]
  • United States Patent (19) (11) Patent Number: 4,782,049 Kappas Et Al
    United States Patent (19) (11) Patent Number: 4,782,049 Kappas et al. (45. Date of Patent: Nov. 1, 1988 (54 TIN PROTOPORPHYRN AND TN 52 U.S. Cl. ..................................... 514/185; 514/863 MESOPORPHYRIN IN THE TREATMENT 58 Field of Search .............................. 514/18 T, 863 OF PSORASIS (56) References Cited (75) Inventors: Attallah Kappas; George S. Drummond, both of New York, N.Y.; U.S. PATENT DOCUMENTS Lennart Emtestam, Huddinge, 4,454,152 6/1984 Barry et al. ......................... 824/283 Sweden 4,657,902 4/1987 Kappas et al. ...................... 514/85 (73) Assignee: The Rockefeller University, New Primary Examiner-Leonard Schenkman York, N.Y. Attorney, Agent, or Firm-Wyatt, Gerber, Burke and (21) Appl. No.: 125,011 Badie 22 Filed: Dec. 2, 1987 (57) ABSTRACT Use of tin protoporphyrin and tin mesoporphyrin to Related U.S. Application Data gether with ultraviolet light in the treatment of psoria (63) Continuation-in-part of Ser. No. 938,822, Dec. 8, 1986, sis. abandoned. (51) Int. Cl* ............................................ A61K 31/555 4 Claims, No Drawings 4,782,049 1. 2 ally in solution or suspension, or topically in a suitable TIN PROTOPORPHYRIN ANDTIN cream or ointment. The patient is exposed to ultraviolet MESOPORPHYRN IN THE TREATMENT OF light as an integral part of the treatment. PSORASIS For parenteral administration any of a wide variety of pharmaceutically acceptable carriers currently in use RELATED APPLICATION for the preparation of therapeutically useful parenteral This application is a continuation-in-part of copend compositions may be employed. These include, for ing application Ser. No. 938,822 filed Dec.
    [Show full text]